BIO-Europe Spring EBD Group BIO BIO-Europe Spring
Share:
Email this page Share this on LinkedIn Share this on Twitter

BIO-Europe Spring® 2015 Press Releases

News for BIO-Europe Spring® 2015 will be available soon.

BIO-Europe Spring 2014 press releases

March 20, 2014BIO-Europe Spring® 2014 partnering event brought over 2,000 life science executives to Turin, Italy last week The eighth annual BIO-Europe Spring® international partnering conference took place last week, March 10–12 in Turin, Italy. The event, held at the Oval Lingotto conference center, welcomed more than 2,000 participants representing over 1,200 companies from 42 countries vying for 2,115 licensing opportunities. More than 10,700 one-to-one meetings took place at the event b...  more ►

March 3, 2014BIO-Europe Spring® 2014 kicks off next week in Turin, ItalyEvent is gathering of life science industry leaders
The eighth annual BIO-Europe Spring® conference kicks off in one week on March 10–12 in Turin, Italy. The event is expected to draw over 2,000 high-level executives from pharma, biotech, venture capital firms, and service companies who will be coming to Turin to engage in one-to-one partnering meetings with innovative biotech startups. Delegates are expected to engage in...  more ►

February 25, 2014"Competition fierce" as big pharma moves to early stage deals The focus for Roche meetings at BIO-Europe Spring® breaks out roughly with a third devoted to ongoing relationships, another third focused on active negotiation and one third opportunistic. "We have to spend more time filtering through that last third, but I can tell you we have found programs over the past year that quickly moved to a high priority status."
more ►

February 12, 2014BIO-Europe Spring® program in Turin will engage executives in provocative topics facing drug development industry Life science executives are quickly filling up the program at the eighth annual BIO-Europe Spring® conference to be held March 10–12, 2014 in Turin, Italy. The international bio-pharma partnering event annually attracts top international executives from established and emerging biotech companies; pharmaceutical companies; private investors including venture capital and priva...  more ►

join the conversation ►

January 29, 2014Spotlight on Turin Business Facts A BUSINESS HUB: According to 2012 data provided by the Register of Enterprises, held by the Torino Chamber of Commerce, the number of businesses based in the Torino Province equals 237,000. LIFE SCIENCES: The Turin Life Science sector comprises medium and large companies operating in the following fields: Medical, Electromedical, and Diagnostic instrumentation; Orthopedic pros...  more ►

join the conversation ►

December 12, 2013Turin, Italy welcomes the 2014 edition of BIO-Europe Spring®Pharmaceutical dealmakers converge upon Italian innovation hub
The eighth annual BIO-Europe Spring® conference will be held March 10–12, 2014 in Turin, Italy at the OVAL Lingotto conference center. The event is recognized by life science insiders as the place for established biotech and early-stage companies to meet and form partnerships with venture capitalists and business development executives from big pharma companies. Investor...  more ►

join the conversation ►


partnering360® Blog

October 24, 2014 Insight into Antigen Express’ immunotherapy Antigen Express is a company who uses their technology to promote immunotherapy to fight many cancers and develop vaccines so that the human body can defend itself. According to a recent article at Insight, their patented peptides are critical in developing immune responses. How does this therapy... more ►

October 23, 2014 Why did only a few European biotechs make it through the IPO window? Guest post from Steve Dickman, CEO, CBT Advisors. Originally posted to Boston Biotech Watch. If the recent falloff in biotech IPOs continues, then many European biotechs would seem to have missed the longest, widest IPO window in the history of the industry. Why did a few European biotechs manage... more ►

October 21, 2014 News from around BIO-Europe® With BIO-Europe just weeks away, many companies are have moved various products along the pipeline and many are seeing success in developing and moving drugs through pipelines: - Apricus Biosciences recently announced that Notice of Allowance for they have received U.S. Patent Application Serial... more ►

October 17, 2014 MediSapiens and Mediconomics look to collaboration for growth To gear up for BIO-Europe®, our team at Insight has spoken with some of the companies coming to the event early next month to see what they’re doing and who they’re looking to meet with at the event. Experimental Therapeutics Centre (ETC), one of a few fully integrated drug discovery... more ►

October 16, 2014 Outtakes from the Stem Cell Meeting on the Mesa 2014 plenary The recent Stem Cell Meeting on the Mesa 2014 opened with a timely plenary session entitled “Cell Therapy Product Development: Maintaining Momentum in the Face of Expected Clinical Challenges.” The panel was chaired by Mark Stevenson, EVP & President, Life Science Solutions, Life... more ►



partnering360:Insight Latest headlines from partnering360:Insight

October 20, 2014 Merck Serono: FIT for partnering and playing with the home court advantage "We are interested in opportunities—spanning from promising drug candidates up to technology platforms—that will support our strategic business objectives, and strengthen our pipeline, our key franchises, and our geographic presence." more ►

October 17, 2014 Antigen Express advances immunotherapy Antigen Express is developing a novel way to boost the immune system, developing a therapeutic platform that can produce off-the-shelf, synthetic peptide vaccines for major diseases, including cancer, HIV, influenza, diabetes and, potentially, Ebola. more ►

October 17, 2014 Third Rock Ventures sees “renaissance of innovation in life sciences” A co-founder of Third Rock Ventures, Kevin Starr focuses on the development and business strategy of the portfolio companies, actively identifying and evaluating new investments. In March, 2013 the firm raised USD 516 million for its Fund III. Several new companies have since been launched and Starr said a further 14 companies will be formed, "most of which are already under consideration inside Third Rock, though we have not announced anything to the outside world yet." more ►

October 13, 2014 Accelerating drug discovery in Singapore creates global successes Building on a string of recent successes, a team from Singapore's Experimental Therapeutics Centre (ETC) arrives in Frankfurt for BIO-Europe® 2014 looking for new opportunities in early stage co-discovery projects. more ►

October 11, 2014 Customized bio-IT solutions are not just for big pharma anymore BIO-Europe® 2014 in Frankfurt will see the soft launch for a bundled product-and-service called the MediSapiens Explorer Platform that brings to small and medium-sized biotechs and pharma companies a platform for managing and accessing massive data sets, and the tools to visualize it in scientist-friendly way. more ►



Arrow Up


 
 
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2014 EBD GmbH
Privacy Policy
Terms of Use
BIO-Europe Spring EBD Group BIO BIO-Europe Spring